Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol vs Ergocalciferol for Secondary Hyperparathyroidism in CKD
NCT00958451Phase 4Completed
- Sponsor
- Salem VA Medical Center
- Start
- Jul 2009
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of paricalcitol oral solution in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Salem VA Medical Center. Primary endpoint: Proportion of patients achieving >= 30% decrease in iPTH at 16 weeks. Started Jul 2009; status: completed.
02
Drugs
paricalcitol oral solution
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00958451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00958451.